Clayton Davis
Family Medicine · Sylacauga, ALNPI 1205923554
Payments from drug & device makers
Across 716 payments — averaging $16.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$1K
- Novo Nordisk$983
- Bayer$813
- AstraZeneca$784
- Lilly USA, LLC$719
- plus $6K from 46 others
What the payments were for
- Food & beverage$11,43299%
- Education$1451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,577 in reported general payments places this provider in the 90th percentile of 1,680 family medicine providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 322 | $264,411 |
| EliquisApixaban | 310 | $223,223 |
| OzempicSemaglutide | 152 | $197,022 |
| FarxigaDapagliflozin Propanediol | 181 | $150,612 |
| MounjaroTirzepatide | 96 | $143,587 |
| XareltoRivaroxaban | 119 | $101,973 |
| EntrestoSacubitril/Valsartan | 118 | $86,903 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 83 | $68,604 |
| TrulicityDulaglutide | 48 | $62,364 |
| JanuviaSitagliptin Phosphate | 123 | $59,359 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 53 | $58,754 |
| RybelsusSemaglutide | 35 | $50,908 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 44 | $47,388 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 45 | $34,436 |
| TrintellixVortioxetine Hydrobromide | 36 | $31,061 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Synjardy | $469 | $313,003379 claims |
| Novo NordiskOzempic, Rybelsus | $983 | $247,930187 claims |
| PfizerEliquis | $404 | $223,223310 claims |
| Lilly USA, LLCMounjaro, Trulicity | $719 | $205,950144 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $784 | $185,049226 claims |
| Johnson & JohnsonXarelto | $1,060 | $101,973119 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $449 | $97,968134 claims |
| NovartisEntresto | $410 | $86,903118 claims |
| MerckJanuvia | $128 | $59,359123 claims |
| AbbVieLinzess, Namzaric | $1,219 | $50,38050 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $217 | $47,38844 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $279 | $31,06136 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Sylacauga
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.